Malecki Law is investigating possible unsuitability claims against stock brokers and financial advisors who sold shares of Amarin to investors for whom the stock was not appropriate.
Amarin is a biopharmaceutical company based out of New Jersey. The company’s primary business involves the development and marketing of medicines used to treat cardiovascular disease. Amarin is best known as the company that developed the pharmaceutical drug Vascepa.
Over the past few years, Amarin has been reportedly seeking various FDA approvals for Vascepa. During the past four to five years, the shares of Amarin have shown great volatility. The shares have gone from roughly $1 per share in February of 2010 up to $19 per share in May of 2011 and back down to just more than $1 per share today. In October 2013, share prices went from more than $7 per share to just over $2 per share in less than two weeks. Again this past October, share prices dropped roughly 50% in only one month’s time.